✦ LIBER ✦

OC-0367 RADIUM-223 CHLORIDE AND IMPROVED SURVIVAL IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES

✍ Scribed by V. Lewington; S. Boehmer; L. Franzén; R. Klijer; B. Mellado; R. Coleman; A. Cross; C. Biggin; C. Parker

Book ID: 119520541
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 66 KB
Volume: 103
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(12)70706-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radium-223 Dichloride: A Review of Its U

Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

✍ Shirley, Matt; McCormack, Paul L. 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 419 KB

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMP

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA)

✍ Sartor, Oliver; Heinrich, Daniel; Helle, Svein Inge; O'Sullivan, Joe M.; Chodack 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

A Randomized, Double-Blind, Dose-Finding

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

✍ Christopher C. Parker; Sarah Pascoe; Aleš Chodacki; Joe M. O'Sullivan; Josep R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 930 KB

Two-Year Survival Follow-Up of the Rando

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

✍ Nilsson, Sten; Franzén, Lars; Parker, Christopher; Tyrrell, Christopher; Blom, R 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 394 KB

Overall Survival Benefit of Radium-223 C

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

✍ C. Parker; D. Heinrich; J.M. O'Sullivan; S. Fossa; A. Chodacki; T. Demkow; A. Cr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

A randomized, dose–response, multicenter

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

✍ S. Nilsson; P. Strang; A.K. Aksnes; L. Franzèn; P. Olivier; A. Pecking; J. Staff 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 512 KB